Evaluating the Use of 0.5 and 0.75 MAC Desflurane in Patients Undergoing Spinal Surgery

Sponsor
Changi General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04717102
Collaborator
(none)
100
1
2
19.5
5.1

Study Details

Study Description

Brief Summary

Background: Somatosensory- (SSEPs) and motor-evoked potentials (MEPs) are commonly used as an intraoperative neurophysiologic monitoring tool to detect aberrations to the spinal cord integrity during spinal surgery. Inhalational anaesthetic agents have a significant influence on evoked potentials by suppressing the amplitude and prolonging the latency. Evidences suggest that total intravenous anaesthesia (TIVA) is superior to inhalation anaesthesia for neuromonitoring in spinal surgery, and support the use of up to 0.5 minimum alveolar concentration (MAC) of inhalational anaesthetic agents in these procedures.

Methods: Patients undergoing spinal surgeries will be prospectively recruited and be induced with TIVA at baseline of the evoked potentials. They will be randomized to receive balance anaesthesia with A) Desflurane MAC 0.5+remifentanil, or B) Desflurane MAC 0.75+remifentanil until the end of surgery. Influence of 1.0 MAC desflurane on the evoked potentials after the completion of surgery will also be studied.

Desired Results: Endpoints include the changes to the amplitude and latency of SSEPs and MEPs with 0.5 and 0.75 MAC desflurane. The findings will indicate the safety of desflurane at the studied concentrations for spinal surgeries, and substantial savings with the use of desflurane instead of TIVA.

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.5 MAC desflurane
  • Drug: 0.75 MAC desflurane
  • Drug: 1.0 MAC desflurane
Phase 4

Detailed Description

Recording of Evoked Potentials characteristics:
The following characteristics of the evoked potential signals will be recorded:
  • Amplitude: Size of the response, measured in microvolts (μV)

  • Latency: Speed of the response, measured in milliseconds (ms)

  • Morphology: Appearance of the response - Simple/Complex wave shape Baseline evoked potentials will be recorded at various points of surgery.

Anaesthesia variables:
At the time of recording of evoked potentials:
  • Intraoperative temperature, blood pressure, ETCO2, anaesthesia depth - bispectral index monitoring (BIS), remifentanil TCI, MAC of desflurane, Train of Four, volume of propofol and remifentanil until randomization, total volume of desflurane and remifentanil used, anaesthetic medications used, FiO2, SpO2
Patient characteristics:
  • Age, gender, race, weight, BMI, medications used, haematocrit, preop blood glucose (for Diabetics)
Safety considerations:

'Recommended standards for intraoperative monitoring of somatosensory evoked potentials', Guideline 11B of the American Clinical Neurophysiology Society (2009) and 'Intraoperative motor evoked potential monitoring - A position statement by the American Society of Neurophysiological Monitoring' will form the basis of the safety aspects of the study.

Conduct of Anaesthesia:
  • The induction of anaesthesia will be achieved using targeted propofol and remifentanil infusions (TIVA). Muscle relaxants atracurium, rocuronium or suxamethonium will be used to facilitate intubation.

  • Anaesthesia will be maintained on TIVA until the patient has recovered from muscle relaxant. Baseline characteristics (BC1) of the evoked potentials in TIVA will be obtained at this stage.

  • Once the BC1 has been obtained, the patients will be randomized to two groups:

Group A- Anaesthesia maintained with 0.5 MAC desflurane/remifentanil infusion Group B- Anaesthesia maintained with 0.75MAC desflurane/remifentanil infusion

  • Baseline characteristics 2 (BC2) will be obtained and the decision to proceed with 0.5 or 0.75 MAC desflurane made.

  • On completion of the neuromonitoring phase of surgery, as defined by completion of instrumentation and start of closure, all patients in Group A and B will be maintained with 1.0 MAC desflurane with remifentanil infusion. Baseline characteristics 3 (BC3) will be recorded at this stage.

  • The remifentanil infusion will be titrated at various stages of surgery to maintain a stable BIS and will also be based on haemodynamic variables.

All patients will get additional analgesics and antiemetics as deemed necessary. Post-operative recovery will follow the standard industry norms.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluating the Use of Desflurane in Patients Undergoing Spinal Surgery: A Randomized Controlled Trial Using 0.5 and 0.75 MAC Desflurane
Actual Study Start Date :
Apr 14, 2021
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: 0.75 MAC desflurane

The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.

Drug: 0.75 MAC desflurane
Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
Other Names:
  • 0.75 MAC desflurane (Suprane)
  • Drug: 1.0 MAC desflurane
    On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
    Other Names:
  • 1.0 MAC desflurane (Suprane)
  • Active Comparator: 0.5 MAC desflurane

    The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.

    Drug: 0.5 MAC desflurane
    Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
    Other Names:
  • 0.5 MAC desflurane (Suprane)
  • Drug: 1.0 MAC desflurane
    On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
    Other Names:
  • 1.0 MAC desflurane (Suprane)
  • Outcome Measures

    Primary Outcome Measures

    1. Effect of 0.5 MAC desflurane on evoked potentials - Amplitude (microvolts) [During surgery]

      Amplitude of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane

    2. Effect of 0.5 MAC desflurane on evoked potentials - Latency (milliseconds) [During surgery]

      Latency of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane

    3. Effect of 0.5 MAC desflurane on evoked potentials - Morphology (appearance of the response) [During surgery]

      Morphology of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane

    4. Effect of 0.75 MAC desflurane on evoked potentials - Amplitude (microvolts) [During surgery]

      Amplitude of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane

    5. Effect of 0.75 MAC desflurane on evoked potentials - Latency (milliseconds) [During surgery]

      Latency of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane

    6. Effect of 0.75 MAC desflurane on evoked potentials - Morphology (appearance of the response) [During surgery]

      Morphology of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane

    Secondary Outcome Measures

    1. Effect of 1.0 MAC desflurane on evoked potentials - Amplitude (microvolts) [intraoperative]

      Amplitude of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane

    2. Effect of 1.0 MAC desflurane on evoked potentials - Latency (milliseconds) [intraoperative]

      Latency of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane

    3. Effect of 1.0 MAC desflurane on evoked potentials - Morphology (appearance of the response) [intraoperative]

      Morphology of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged ≥ 21 years old, scheduled for spinal surgery.

    • Patients who require SSEP/MEP and with no neurological deficits.

    • Patients of American Society of Anesthesiologist I-III physical status.

    • Consenting patients.

    • Elective procedures.

    Exclusion Criteria:
    • Patients with sensory or motor deficits preoperatively.

    • Patients with significant cardiovascular and/or respiratory disease.

    • Emergency procedures.

    • Cord injury secondary to trauma.

    • Non-consenting patients.

    • Category A patients (Prisoners).

    • Patients with previous stroke.

    • Patients with Hep C, HIV.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Changi General Hospital Singapore Singapore 529889

    Sponsors and Collaborators

    • Changi General Hospital

    Investigators

    • Principal Investigator: Wai May Leong, MMed, Changi General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Leong Wai May, Senior Consultant, Changi General Hospital
    ClinicalTrials.gov Identifier:
    NCT04717102
    Other Study ID Numbers:
    • Desflurane01
    First Posted:
    Jan 20, 2021
    Last Update Posted:
    Aug 6, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Leong Wai May, Senior Consultant, Changi General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 6, 2021